Back to top

Analyst Blog

Mylan Inc.’s (MYL - Analyst Report) generic unit is its main growth driver. Bulk of the revenues of the company is generated from generic third-party net sales, derived from sales in North America, Europe, the Middle East & Africa (EMEA) and Asia-Pacific. Moreover, Mylan has a strong generic pipeline and the company should continue benefiting from a large number of high-value branded drugs scheduled to go off patent in the next couple of years. These patent expirations should boost the generic product portfolio of Mylan.

Mylan is locked in multiple legal tussles over a number of generic applications. For example, Mylan was sued by the privately held Aptalis Pharma earlier this year. The patent challenge followed Mylan’s filing of an abbreviated new drug application (ANDA) as it sought to market its generic version of Aptalis Pharma’s ulcerative proctitis drug Canasa (mesalamine).

Forest Laboratories and Royalty Pharma Collection Trust sued Mylan over the ANDA filed by the generic company with the U.S. Food and Drug Administration (FDA) for its generic version of Savella (milnacipran HCl tablets) at 12.5 mg, 25 mg, 50 mg and 100 mg dosages. The branded version of the drug is approved (not in pediatrics) for fibromyalgia management.

Mylan believes it may be the first-to-file an ANDA for a generic version of Savella. If this is the case, Mylan would be entitled to 180 days of exclusivity on gaining approval from the FDA. As per IMS Health data, Savella sales in the U.S. were $123 million for the twelve months ended Jun 30, 2013.

Mylan, one of the largest players in the global generics market, has a presence in more than 140 countries. As of Sep 25, 2013, the company had 178 ANDAs pending FDA approval, representing $83.8 billion in annual sales. These include 42 first-to-file opportunities, representing $23.8 billion in annual sales. The data released by IMS Health is for the twelve-month period ending Dec. 31, 2012.

The segment has seen quite a few launches over the past few months. One of the important recent launches includes the company's generic version of Pfizer Inc.’s (PFE - Analyst Report) erectile dysfunction drug Viagra.  

Mylan carries a Zacks Rank #2 (Buy). Actavis, Inc. (ACT - Analyst Report) is another Zacks #2 Ranked stock in the generic space.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%